Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2023-02-21 00:00:00 ET · period of report 2023-02-16 · accession 0001209191-23-011447 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-21 | 2023-02-16 | BBIO | Kumar Neil | CEO, Pres, Dir | F - Tax | $12.64 | -23.9K | 4.86M | -0.5% | -$302.2K |
| D | 2023-02-21 | 2023-02-16 | BBIO | Kumar Neil | CEO, Pres, Dir | M - OptEx | — | +68.7K | 4.88M | +1% | — |
| D | 2023-02-21 | 2023-02-17 | BBIO | Kumar Neil | CEO, Pres, Dir | S - Sale+OE | $12.70 | -44.8K | 4.81M | -0.9% | -$568.9K |
| DM | 2023-02-21 | 2023-02-16 | BBIO | Kumar Neil | CEO, Pres, Dir | M - OptEx | $0.00 | -68.7K | 25.6K | -73% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-16 | F | D | 23,908 | $12.64 | 4,857,995 | D | — | — | (F2) Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 68,705 shares of Common Stock underlying the Reporting Person's RSUs. |
| 2 | Common | Common Stock | 2023-02-16 | M | A | 68,706 | — | 4,881,903 | D | — | — | (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| 3 | Common | Common Stock | 2023-02-17 | S | D | 44,798 | $12.70 | 4,813,197 | D | — | — | (F4) Represents the weighted average sale price of the shares sold from $12.13 to $13.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein. |
| 4 | Derivative | Restricted Stock Units | 2023-02-16 | M | D | 61,182 | $0.00 | 244,728 | D | — · — to — | 61,182 Common Stock | (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F9) The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. |
| 5 | Derivative | Restricted Stock Units | 2023-02-16 | M | D | 2,395 | $0.00 | 19,153 | D | — · — to — | 2,395 Common Stock | (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F8) The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. |
| 6 | Derivative | Restricted Stock Units | 2023-02-16 | M | D | 5,129 | $0.00 | 25,647 | D | — · — to — | 5,129 Common Stock | (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F7) The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. |